Celgene paid Sutro $95M upfront (including equity) plus up to $90M in research-term payments for multi-year rights to discover bispecific antibodies and ADCs against immuno-oncology targets including PD-1/PD-L1 using Sutro's cell-free XpressCF platform.
Key facts
AnnouncedOct 24, 2014
ClosedOct 24, 2014
Deal value$185M
Deal typeCo-Development
Therapeutic areaMultiple cancers including PD-1/PD-L1 combinations
IndicationsMultiple cancers including PD-1/PD-L1 combinations
Key assetsMultispecific antibodies and antibody-drug conjugates
MechanismCell-free antibody and ADC discovery (XpressCF platform)